GlassScriptPhysician profile
James P Hopper
NPI 1144306283
$1,127.87
in general payments reported to CMS, 2019-2025
15 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.20 · 2023: $275 · 2024: $518 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.41 | 2022-2025 | |
| Novo Nordisk INC | $217.13 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $142.02 | 2023-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Pfizer INC. | $127.40 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $108.95 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $80.55 | 2024-2025 | Repatha, Otezla, Otezla |
| Hologic Sales and Service, LLC | $37.01 | 2023 | Aptima |
| Astellas Pharma US INC | $23.73 | 2024 | Veozah |
| Dexcom, INC. | $22.91 | 2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $20.98 | 2025 | Slynd |
| Lilly USA, LLC | $20.48 | 2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $20.40 | 2023 | |
| Phathom Pharmaceuticals, INC. | $19.19 | 2024 | Voquezna |
| Exact Sciences Corporation | $15.46 | 2024 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $14.25 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.